Powered by

New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease: Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis

Oct 22, 2014 - PR Newswire

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces that Dr. Tomer Adar, a gastro-enterologist at the Institute for Digestive Diseases at Shaare Zedek Medical Center, Israel, is presenting today at the United European Gastro-Enterology week in Vienna, Austria an abstract entitled "The importance of intestinal eotaxin-1 - Eosinophil axis in inflammatory bowel disease, Results of a prospective observational study." The study was supported in part by an unrestricted gr...